Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SITAGLIPTIN Cause Peripheral venous disease? 13 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Peripheral venous disease have been filed in association with SITAGLIPTIN (JANUVIA). This represents 0.1% of all adverse event reports for SITAGLIPTIN.

13
Reports of Peripheral venous disease with SITAGLIPTIN
0.1%
of all SITAGLIPTIN reports
11
Deaths
11
Hospitalizations

How Dangerous Is Peripheral venous disease From SITAGLIPTIN?

Of the 13 reports, 11 (84.6%) resulted in death, 11 (84.6%) required hospitalization, and 4 (30.8%) were considered life-threatening.

Is Peripheral venous disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for SITAGLIPTIN. However, 13 reports have been filed with the FAERS database.

What Other Side Effects Does SITAGLIPTIN Cause?

Blood glucose increased (1,427) Pancreatic carcinoma (1,142) Product dose omission issue (1,125) Drug ineffective (1,057) No adverse event (994) Nausea (936) Pancreatitis (922) Diabetes mellitus inadequate control (744) Diarrhoea (712) Hypoglycaemia (674)

What Other Drugs Cause Peripheral venous disease?

RITUXIMAB (1,281) ADALIMUMAB (1,249) METHOTREXATE (1,246) SECUKINUMAB (1,186) ABATACEPT (1,168) DICLOFENAC (1,168) LEFLUNOMIDE (1,154) TOCILIZUMAB (1,137) PREDNISONE (1,101) ALENDRONATE (1,097)

Which SITAGLIPTIN Alternatives Have Lower Peripheral venous disease Risk?

SITAGLIPTIN vs SOAP SITAGLIPTIN vs SODIUM SITAGLIPTIN vs SODIUM BICARBONATE SITAGLIPTIN vs SODIUM BICARBONATE\SODIUM SITAGLIPTIN vs SODIUM BORATE

Related Pages

SITAGLIPTIN Full Profile All Peripheral venous disease Reports All Drugs Causing Peripheral venous disease SITAGLIPTIN Demographics